Invention of the capsulorhexisFriday, December 7, 2018
Inspiration, perspiration and a small degree of good fortune were the key ingredients in the invention of the capsulorhexis,
Diabetic eye disease epidemiologySunday, September 23, 2018
THE 24.7 per cent prevalence of reported diabetic eye disease in Europe is much lower than the global burden of 34.6 per cent
Cataract surgery riskSunday, September 23, 2018
What is the risk of cataract surgery in the diabetic patient?
New concepts and treatments for diabetesSunday, September 23, 2018
Discussion on key issues of diabetes regarding complications of the disease and side effects of common treatments.
EURETINA Race Run in Prater ParkSunday, September 23, 2018
TORRENTIAL rain did not deter the dozens of ophthalmologists, scientists and exhibitors who turned out at dawn yesterday to take part in the Retina Race 2018.
EURETINA comes of ageFriday, September 21, 2018
This year marks a real coming of age for the European Society of Retina Specialists, says society president Sebastian Wolf
Management of neovascular AMDFriday, September 21, 2018
Contemporary management of neovascular age-related macular degeneration (AMD) has evolved significantly over the last few years.
EURETINA Video Competition prizes presentedFriday, September 21, 2018
The winners of this year’s EURETINA Video Competition demonstrate how difficult cases can lead to surgical innovations.
Achievements and challenges of current anti-VEGF therapyFriday, September 21, 2018
Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration, significantly reducing AMD-associated blindness and visual impairment in the process, according to Ursula Schmidt-Erfurth MD, PhD, at a special session on the EURETINA Guidelines for Management of Retinal Disease yesterday. Highlighting the achievements and challenges of current anti-VEGF therapy, Dr Schmidt-Erfurth said that intravitreal […]
Macustar project seeks novel endpointsFriday, September 21, 2018
MACUSTAR project, to seek novel clinical endpoints for clinical trials in iAMD so that interventional studies can be implemented.”